Global Enzyme Linked Immunospot Assays Market – Industry Trends and Forecast to 2029

Request for TOC Request for TOC Speak to Analyst Speak to Analyst Buy Now Buy Now Inquire Before Buying Inquire Before Free Sample Report Free Sample Report

Global Enzyme Linked Immunospot Assays Market – Industry Trends and Forecast to 2029

  • Healthcare
  • Upcoming Report
  • Aug 2022
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Global Enzyme Linked Immunospot Assays Market

Market Size in USD Billion

CAGR :  % Diagram

Diagram Forecast Period
2022 –2029
Diagram Market Size (Base Year)
USD 493.77 Million
Diagram Market Size (Forecast Year)
USD 711.93 Million
Diagram CAGR
%
Diagram Major Markets Players
  • Dummy1
  • Dummy2
  • Dummy3
  • Dummy4
  • Dummy5

Global Enzyme Linked Immunospot Assays Market, By Test Type (Sandwich ELISA, Indirect ELISA, Multiple and Portable ELISA, Competitive ELISA), Application (Immunology, Inflammation, Infectious Diseases, Cancer, Protein Quantitation, Other) – Industry Trends and Forecast to 2029

Enzyme Linked Immunospot Assays Market

Enzyme Linked Immunospot Assays Market Analysis and Size

According to the Globocan 2020, there were roughly 9,958,133 cancer-related deaths worldwide and an estimated 19,292,789 new cancer cases that were identified. Additionally, the International Agency for Research on Cancer (IARC) predicts that by 2040, there will be 16.3 million cancer-related deaths globally and 27.5 million new instances of cancer. The enzyme linked immunospot assays demand is anticipated to be driven by the rising number of cancer cases.

Data Bridge Market Research analyses that the enzyme linked immunospot assays market which was USD 493.77 million in 2021, would rocket up to USD 711.93 million by 2029, and is expected to undergo a CAGR of 4.68% during the forecast period 2022 to 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Enzyme Linked Immunospot Assays Market Scope and Segmentation

Report Metric

Details

Forecast Period

2022 to 2029

Base Year

2021

Historic Years

2020 (Customizable to 2014 - 2019)

Quantitative Units

Revenue in USD Million, Volumes in Units, Pricing in USD

Segments Covered

Test Type (Sandwich ELISA, Indirect ELISA, Multiple and Portable ELISA, Competitive ELISA), Application (Immunology, Inflammation, Infectious Diseases, Cancer, Protein Quantitation, Other)

Countries Covered

U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

Market Players Covered

Thermo Fisher Scientific Inc. (U.S.), BD (U.S.), Bio-Rad Laboratories, Inc. (U.S.), bioMérieux (France), Merck KGaA (Germany), RayBiotech Life Inc. (U.S.), R&D Systems, Inc. (U.S.), AESKU.GROUP GmbH & Co. KG (Germany), Eurofins Scientific (Luxembourg), Biogenuix (India), F. Hoffmann-La Roche Ltd (Switzerland), Abbott (U.S.), Danaher (U.S.), Sysmex Corporation (Japan), PerkinElmer Inc. (U.S.), Agilent Technologies Inc. (U.S.)

Market Opportunities

  • Increasing incidence of chronic diseases
  • Technological breakthroughs in test kits and analyzers for enzyme linked immunospot assays

Market Definition

The enzyme linked immunospot (ELISpot) assays is a fundamental tool in cellular immunology, providing both quantitative and qualitative information on cellular cytokine responses to defined antigens. In order to identify CD8+ T cells that are specific to an epitope, the enzyme-linked immunospot (ELISPOT) assays is a sensitive immunologic technique that measures cytokine release on a single-cell basis. A putative antigenic peptide is delivered to CD8+ T lymphocytes via MHC-I on antigen-presenting cells (APCs). ELISpot assays are quicker, more trustworthy, and less expensive than other functional assays (e.g., ICS). They are especially well suited for screenings because of their great sensitivity and simplicity of use.

Enzyme Linked Immunospot Assays Market Dynamics

Drivers

  • Increase in diagnostic technologies

According to the World Health Organization, over 354 million individuals worldwide are estimated to have hepatitis B or C infections in 2020. The need for a diagnosis arise due to the rising occurrence of infectious diseases. The expansion of the market is related to the rising use of cutting-edge diagnostic technologies for illness screening, such as enzyme linked immunosorbent assays.

  • Rising chronic diseases

According to the World Health Organization's December 2020 report, the major chronic diseases currently account for over 60% of all fatalities and 43% of the burden of disease globally. By 2020, it is anticipated that their share of global morbidity and mortality will reach 60% and 73 percent, respectively. Additionally, chronic diseases account for 79 percent of mortality in underdeveloped nations. Additionally, market expansion is anticipated to be fuelled by technological advancements in assay kits and analyzers for enzyme linked immunosorbent assay.

  • Rising healthcare expenditure

According to the Center for Disease Control and Prevention 2021, the leading causes of mortality and disability in the United States are chronic diseases like heart disease, cancer, and diabetes. Additionally, they are primarily responsible for the USD 3.8 trillion in annual healthcare expenditures in the US. As a result of increasing healthcare costs and the incidence of chronic diseases, the market is expected to rise throughout the forecast period.

Opportunities

  • Increase in the number of research and development activities 

The market's growth is fuelled by rising number of patients with infectious diseases around the world, the proliferation of innovative and novel products, and the use of advanced technology for multiple diagnosis are expected to boost the growth of the enzyme linked immunospot assays market.

On the other hand, throughout the forecast period, the market will expand due to the launch of numerous medications that will further boost potential of the market.

Restraints/Challenges

On the other hand, the easy availability of alternative methods will obstruct the market's growth rate.

This enzyme linked immunospot assays market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the enzyme linked immunospot assays market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Enzyme Linked Immunospot Assays Market

Enzyme-linked immunosorbent assay (ELISA) demand has surged due to the COVID-19 all over the world. The main cause of this is the rise in infection rates, which increased the demand for accurate diagnosis. Data from the National Center for Biotechnology Information (NCBI) Journal in 2020 show that SARS-CoV-2 can be accurately detected using the enzyme-linked immunosorbent assay (ELISA). The demand for more affordable and accurate diagnosis in order to receive the right treatment is anticipated to fuel market expansion.

Global Enzyme Linked Immunospot Assays Market Scope

The enzyme linked immunospot assays market is segmented on the basis of test type and application. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Test Type

  • Sandwich ELISA
  • Indirect ELISA
  • Multiple and Portable ELISA
  • Competitive ELISA

 Application

  • Immunology
  • Inflammation
  • Infectious Diseases
  • Cancer
  • Protein Quantitation
  • Other

Enzyme Linked Immunospot Assays Market Regional Analysis/Insights

The enzyme linked immunospot assays market is analysed and market size insights and trends are provided by country, test type and application as referenced above.

The countries covered in the enzyme linked immunospot assays market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the enzyme linked immunospot assays market owing to the emergence in the abundance of businesses, developed healthcare foundation, and the extent of communicable disorders and the improvement of several innovative commodities.

Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2022 to 2029 due to the rising number of patient population along with developing of infrastructure and adoption of diagnostic tools.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Competitive Landscape and Enzyme Linked Immunospot Assays Market Share Analysis

The enzyme linked immunospot assays market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to enzyme linked immunospot assays market.

Some of the major players operating in the enzyme linked immunospot assays market are:

  • Thermo Fisher Scientific Inc. (U.S.)
  • BD (U.S.)
  • Bio-Rad Laboratories, Inc. (U.S.)
  • bioMérieux (France)
  • Merck KGaA (Germany)
  • RayBiotech Life Inc. (U.S.)
  • R&D Systems, Inc. (U.S.)
  • AESKU.GROUP GmbH & Co. KG (Germany)
  • Eurofins Scientific (Luxembourg)
  • Biogenuix (India)
  • F. Hoffmann-La Roche Ltd (Switzerland)
  • Abbott (U.S.)
  • Danaher (U.S.)
  • Sysmex Corporation (Japan)
  • PerkinElmer Inc. (U.S.)
  • Agilent Technologies Inc. (U.S.)


SKU-

Get online access to the report on the World's First Market Intelligence Cloud

  • Interactive Data Analysis Dashboard
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
  • Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Request for Demo

Research Methodology

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Customization Available

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Frequently Asked Questions

The Enzyme Linked Immunospot Assays Market size will be worth USD 711.93 million by 2029.
The Enzyme Linked Immunospot Assays Market growth rate is 4.68% by 2029.
Increase in diagnostic technologies, Rising chronic diseases and Rising healthcare expenditure are the growth drivers of the Enzyme Linked Immunospot Assays Market.
The test type and application are the factors on which the Enzyme Linked Immunospot Assays Market research is based.
The major companies in the Enzyme Linked Immunospot Assays Market are Thermo Fisher Scientific Inc. (U.S.), BD (U.S.), Bio-Rad Laboratories, Inc. (U.S.), bioMérieux (France), Merck KGaA (Germany), RayBiotech Life Inc. (U.S.), R&D Systems, Inc. (U.S.), AESKU.GROUP GmbH & Co. KG (Germany), Eurofins Scientific (Luxembourg), Biogenuix (India), F. Hoffmann-La Roche Ltd (Switzerland), Abbott (U.S.), Danaher (U.S.), Sysmex Corporation (Japan), PerkinElmer Inc. (U.S.), Agilent Technologies Inc. (U.S.).